StockData
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. (ENVB) stock

ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.44−0.07 (-4.95%)

Close on Nov 16, 2026Market cap $6.45MP/E –Yield –

Enveric Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Enveric Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.56M. For fiscal 2025 it was -$8.14M. The highest annual figure on record is -$21.63K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.14M–
FY2024Dec 31, 2024-$7.73M–
FY2023Dec 31, 2023-$14.09M–
FY2022Dec 31, 2022-$17.15M–
FY2021Dec 31, 2021-$11.46M–
FY2020Dec 31, 2020-$3.89M–
FY2019Dec 31, 2019-$647.86K–
FY2018Dec 31, 2018-$2.57M–
FY2017Dec 31, 2017-$2.74M–
FY2016Dec 31, 2016-$2.70M–
FY2015Dec 31, 2015-$3.90M–
FY2014Dec 31, 2014-$43.16K–
FY2013Dec 31, 2013-$21.63K–
FY2012Dec 31, 2012-$24.85K–
FY2011Dec 31, 2011-$30.35K–
FY2010Dec 31, 2010-$40.67K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.44M–
Q1 FY2026Mar 31, 2026-$2.26M–
Q4 FY2025Dec 31, 2025-$1.78M–
Q3 FY2025Sep 30, 2025-$2.07M–
Q2 FY2025Jun 30, 2025-$1.89M–
Q1 FY2025Mar 31, 2025-$2.39M–
Q4 FY2024Dec 31, 2024-$1.31M–
Q3 FY2024Sep 30, 2024-$927.07K–
Q2 FY2024Jun 30, 2024-$2.89M–
Q1 FY2024Mar 31, 2024-$2.60M–
Q4 FY2023Dec 31, 2023-$1.75M–
Q3 FY2023Sep 30, 2023-$2.74M–
Q2 FY2023Jun 30, 2023-$4.47M–
Q1 FY2023Mar 31, 2023-$5.14M–
Q4 FY2022Dec 31, 2022-$3.46M–
Q3 FY2022Sep 30, 2022-$4.55M–
Q2 FY2022Jun 30, 2022-$4.59M–
Q1 FY2022Mar 31, 2022-$4.55M–
Q4 FY2021Dec 31, 2021-$4.07M–
Q3 FY2021Sep 30, 2021-$2.21M–
Q2 FY2021Jun 30, 2021-$2.02M–
Q1 FY2021Mar 31, 2021-$3.16M–
Q4 FY2020Dec 31, 2020-$2.25M-372.3%
Q3 FY2020Sep 30, 2020-$393.74K–
Q2 FY2020Jun 30, 2020-$351.13K–
Q1 FY2020Mar 31, 2020-$893.92K–
Q4 FY2019Dec 31, 2019$826.30K–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019-$490.02K-371.9%
Q1 FY2019Mar 31, 2019-$984.13K–
Q4 FY2018Dec 31, 2018-$1.00M–
Q3 FY2018Sep 30, 2018-$1.28M–
Q2 FY2018Jun 30, 2018$180.21K–
Q1 FY2018Mar 31, 2018-$459.56K–
Q4 FY2017Dec 31, 2017-$941.22K-420.6%
Q3 FY2017Sep 30, 2017-$98.58K–
Q2 FY2017Jun 30, 2017-$863.06K–
Q1 FY2017Mar 31, 2017-$837.93K–
Q4 FY2016Dec 31, 2016$293.58K–
Q3 FY2016Sep 30, 2016-$2.83M–

More Enveric Biosciences figures

See a number that looks wrong?